CYRX Stock Overview
Provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cryoport, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.09 |
| 52 Week High | US$20.11 |
| 52 Week Low | US$5.32 |
| Beta | 1.63 |
| 11 Month Change | -1.25% |
| 3 Month Change | -21.22% |
| 1 Year Change | -48.77% |
| 33 Year Change | -88.61% |
| 5 Year Change | -52.67% |
| Change since IPO | -93.61% |
Recent News & Updates
Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Nov 06
The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More
Aug 09Recent updates
Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Nov 06The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More
Aug 09Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?
Jul 22Slammed 28% Cryoport, Inc. (NASDAQ:CYRX) Screens Well Here But There Might Be A Catch
Jun 25Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk
Apr 15Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 15Cryoport Tanks On Chilling Results And Bad Decisions
Mar 14Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?
Mar 10Fewer Investors Than Expected Jumping On Cryoport, Inc. (NASDAQ:CYRX)
Jan 15Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?
Oct 06Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term
Jul 23Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity
Jul 12Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Jun 13Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price
Mar 06Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially
Nov 07Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?
Sep 23Cryoport: A Rare Investing Opportunity
Sep 22Cryoport enters into strategic relationship with Takeda's BioLife Plasma Services
Sep 08Cryoport: Rapid Growth Is Great, But Shares Look Overpriced
Jul 30Cryoport: To Resume Aggressive Growth
May 11Cryoport: An Industry Leader Basking In Industry Tailwinds
Apr 15Cryoport: Risky Investment With Upside Potential
Apr 01Cryoport: More Growth Going Into New Year 2022
Dec 29Is Cryoport, Inc. (NASDAQ:CYRX) Trading At A 49% Discount?
Dec 05Shareholder Returns
| CYRX | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 7.9% | 3.9% | 1.6% |
| 1Y | -48.8% | 4.7% | 32.3% |
Return vs Industry: CYRX underperformed the US Life Sciences industry which returned 4.8% over the past year.
Return vs Market: CYRX underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| CYRX volatility | |
|---|---|
| CYRX Average Weekly Movement | 8.9% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CYRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CYRX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,100 | Jerry Shelton | www.cryoportinc.com |
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services.
Cryoport, Inc. Fundamentals Summary
| CYRX fundamental statistics | |
|---|---|
| Market cap | US$354.91m |
| Earnings (TTM) | -US$166.47m |
| Revenue (TTM) | US$226.11m |
1.5x
P/S Ratio-2.1x
P/E RatioIs CYRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYRX income statement (TTM) | |
|---|---|
| Revenue | US$226.11m |
| Cost of Revenue | US$130.50m |
| Gross Profit | US$95.61m |
| Other Expenses | US$262.08m |
| Earnings | -US$166.47m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.37 |
| Gross Margin | 42.28% |
| Net Profit Margin | -73.62% |
| Debt/Equity Ratio | 47.6% |
How did CYRX perform over the long term?
See historical performance and comparison